Antibody therapy, which encompasses convalescent plasma, hyperimmune globulin, and monoclonal antibodies, is an intriguing and potentially important component of COVID-19 therapeutics. In this conversation with Dr. Ryan Metcalf, director of the University of Utah’s transfusion services, we discuss the current thinking around convalescent plasma therapy and why we need more formal clinical trials of therapies for emerging diseases.